Testing a new blood cancer drug for patients whose disease returned

Plain-English translation of NCT07139873 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated June 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new medication called to see if it can help people whose chronic lymphocytic leukemia or small lymphocytic lymphoma has returned or stopped responding to previous treatment. About 250 patients will be randomly assigned to either take this medication daily or receive their doctor's choice of standard treatment. The main goal is to measure how long the medication helps keep the cancer from getting worse.

People with blood cancers that come back after initial treatment need better options. This trial exists to find out whether this medication offers a meaningful improvement in controlling the disease compared to other available treatments.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or is not responding to prior treatment
your doctor believes you need treatment for your condition
you have adequate bone marrow function and organ health
you are willing to follow contraceptive restrictions during the study

You likely don't qualify if…

you have any unresolved side effects from previous treatment
you have suspected transformation of your cancer to a more aggressive form (Richter transformation)
you have known or suspected spread of cancer to your brain or central nervous system
you have serious heart disease, an active infection, another cancer, or an uncontrolled medical condition
you cannot swallow pills or have digestive problems that would prevent you from absorbing the medication properly

What participation looks like

If you join this trial, you will be randomly assigned to either take as a daily pill or receive your doctor's standard choice of treatment. You will have regular visits with the research team to check how well the treatment is working, monitor for side effects, and have blood tests. The study will track how long your cancer stays controlled to compare the effectiveness of the two treatment options.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(2 sites)

China

First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu

National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, Tianjin Municipality